Cited by 458Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative DiseasesDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

Open access

Brunden, Kurt R., Trojanowski, John Q., Lee, Virginia M.-Y.·2009·Nature Reviews Drug Discovery

DOI 10.1038/nrd2959PMC PMC2787232

Open this paper in CoChat — free account

Abstract

Neuronal inclusions comprised of the microtubule-associated protein tau are found in numerous neurodegenerative diseases, commonly known as tauopathies. In Alzheimer's disease - the most prevalent tauopathy - misfolded tau is probably a key pathological agent. The recent failure of amyloid-beta-targeted therapeutics in Phase III clinical trials suggests that it is timely and prudent to consider alternative drug discovery strategies for Alzheimer's disease. Here, we focus on strategies directed at reducing misfolded tau and compensating for the loss of normal tau function.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrd2959

Cites

140 of 140 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Neurodegenerative Tauopathies
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Self-citation
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Self-citation
Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work.
Buée, L., Bussière, T., Buée‐Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,133
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Extensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study
Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., & Cuervo, A. M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.113 · Cited by 1,588
The distribution of tau in the mammalian central nervous system.
Binder, L. I., Frankfurter, A., & Rebhun, L. I. (1985) · The Journal of cell biology · doi:10.1083/jcb.101.4.1371 · Cited by 1,588

Flagged first, then by citations

Show all 140 references

Research works printed but not linked: 3

Avila, J. Tau and tauopathies: tau phosphorylation and tau assembly. FEBS J. 273, 23 (2006).
Alonso, A. D., GrundkeIqbal, I. & Iqbal, K. Abnormally phosphorylated tau from Alzheimer disease brain depolymerizes microtubules. Neurobiol. Aging 15, S37 (1994).
Schneider, A., Biernat, J., von Bergen, M., Mandelkow, E. & Mandelkow, E. M. Phosphorylation that detaches tau from microtubules S262 and S214 protects it against aggregation into Alzheimer paired helical filaments. J. Neurochem. 73, S26 (1999).

Sorted by citations

Items 301–400 of 458

Amyloid Beta and Tau: from Physiology to Pathology in Alzheimer’s Disease
Khaledi, S., ایران, گ. ع. ز. د. ع. د. ک. س., Ahmadi, S., & ایران, گ. ع. ز. د. ع. د. ک. س. (2016) · The Neuroscience Journal of Shefaye Khatam · doi:10.18869/acadpub.shefa.4.4.67 · Cited by 14
Differences in the frequency of Alzheimer's disease‐associated genomic variations in populations of different races
Huang, P.-Y. S., Hsieh, S., Chang, Y., Hour, A., Chen, H., & Liu, C. (2017) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.13059 · Cited by 14
Protection of Beta Boswellic Acid against Streptozotocin-induced Alzheimerʼs Model by Reduction of Tau Phosphorylation Level and Enhancement of Reelin Expression
Shasaltaneh, M. D., Naghdi, N., Ramezani, S., Alizadeh, L., & Riazi, G. H. (2021) · Planta Medica · doi:10.1055/a-1502-7083 · Cited by 14
Systematically Studying the Effect of Small Molecules Interacting with RNA in Cellular and Preclinical Models
Bush, J. A., Williams, C. C., Meyer, S. M., Tong, Y., Haniff, H. S., Childs‐Disney, J. L., & Disney, M. D. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00014 · Cited by 14
A small‐molecule microtubule‐stabilizing agent safely reduces Aβ plaque and tau pathology in transgenic mouse models of Alzheimer's disease
Yao, Y., Muench, M., Alle, T., Zhang, B., Lucero, B., Perez‐Tremble, R., McGrosso, D., Newman, M., Gonzalez, D. J., Lee, V. M. ‐., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13875 · Cited by 13
Self-citation
Targeting Tau Protein with Proximity Inducing Modulators: A New Frontier to Combat Tauopathies
Uliassi, E., Bolognesi, M. L., & Milelli, A. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00733 · Cited by 13
Hypothesis on ontogenesis and pathophysiology of Alzheimer’s disease
Schwab, E. D. P., Queiroz, R., Fiebrantz, A. K. B., Bastos, M., Bonini, J. S., & da Silva, W. C. F. N. (2022) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2022rw0170 · Cited by 13
Neuroprotective effects of Hu-Yi-Neng, a diet supplement, On SH-SY5Y human neuroblastoma cells
Yang, Y., Hsieh, T., Tsai, M.-L., Chen, C.-H., Lin, H.-Y., & Wu, S.-J. (2013) · The journal of nutrition health & aging · doi:10.1007/s12603-013-0382-3 · Cited by 13
Effects of C7 substitutions in a high affinity microtubule-binding taxane on antitumor activity and drug transport
Xiao, X., Ju, W., Trigili, C., Chen, H., Chu, J. W. K., Zhao, Y., Lu, P., Li, S., Li, Y., Sharom, F. J., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.06.034 · Cited by 13
Affecting RNA biology genome-wide by binding small molecules and chemically induced proximity
Baisden, J. T., Childs‐Disney, J. L., Ryan, L. S., & Disney, M. D. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.03.006 · Cited by 12
N-Amination Converts Amyloidogenic Tau Peptides into Soluble Antagonists of Cellular Seeding
Makwana, K. M., Sarnowski, M. P., Miao, J., Lin, Y., & Valle, J. R. D. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00528 · Cited by 12
Neurodegenerative diseases
Rang, H. P., Dale, M. M., Ritter, J. M., Flower, R. J., & Henderson, G. (2012) · Elsevier eBooks · doi:10.1016/b978-0-7020-3471-8.00039-1 · Cited by 12
Molecular Docking Studies, Bioactivity Score Prediction, Drug Likeness Analysis of GSK-3 β Inhibitors: A Target Protein Involved in Alzheimer’s Disease
Joshi, A., Kumar, R., & Sharma, A. (2018) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/2650 · Cited by 12
Impact of GSK-3β and CK-1δ on Wnt signaling pathway in alzheimer disease: A dual target approach
Sharma, V., Sharma, P. C., Reang, J., Yadav, V., Tonk, R. K., Majeed, J., & Sharma, K. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107378 · Cited by 11
Tubulin transforms Tau and α-synuclein condensates from pathological to physiological
Lucas, L., Tsoi, P. S., Quan, M. D., Choi, K., Ferreon, J. C., & Ferreon, A. C. M. (2026) · Nature Communications · doi:10.1038/s41467-026-69618-3 · Cited by 11
Current Trends in the Development of Drugs for the Treatment of Alzheimer’s Disease and their Clinical Trials
Бачурин, С. О., Bovina, E. V., & Ustyugov, A. A. (2018) · Biomedical Chemistry Research and Methods · doi:10.18097/bmcrm00015 · Cited by 11
Abnormal cortical regions and subsystems in whole brain functional connectivity of mild cognitive impairment and Alzheimer’s disease: a preliminary study
Chen, B. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01539-7 · Cited by 11
Merocyanine Complexes Coupled with Plasmonic Au Nanoparticles for Inhibiting Tau Aggregation
Wu, Y.-C., Wu, C.-Y., Tsai, S.-W., Chen, H.-J., Liu, W.-J., Lin, D., Gong, T., Yong, K., & Kong, K. V. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.2c03326 · Cited by 11
Identification of tanshinone IIA as a natural monoacylglycerol lipase inhibitor by combined in silico and in vitro approach
Yang, R., Yang, L., & Liu, J. (2014) · MedChemComm · doi:10.1039/c4md00186a · Cited by 11
Impaired hippocampal and thalamic acetylcholine release in P301L tau-transgenic mice
Stein, C., Koch, K. A., Hopfeld, J., Lobentanzer, S., Lau, H., & Klein, J. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.07.014 · Cited by 11
Clearance of the intracellular high level of the Tau protein directed by an artificial synthetic hydrolase
Chu, T., Li, Q.-Q., Qiu, T., Sun, Z., Hu, Z., Chen, Y., Zhao, Y., & Li, Y. (2014) · Molecular BioSystems · doi:10.1039/c4mb00508b · Cited by 11
Behavioural variant frontotemporal dementia: Clinical and therapeutic approaches
Fernández‐Matarrubia, M., Matías‐Guiu, J. A., Moreno‐Ramos, T., & Matías‐Guiu, J. (2014) · Neurología (English Edition) · doi:10.1016/j.nrleng.2013.03.004 · Cited by 11
Pathobiolgy and Management of Alzheimer's Disease
Kim, H., & Chung, J. Y. (2021) · Chonnam Medical Journal · doi:10.4068/cmj.2021.57.2.108 · Cited by 11
Crossing Barriers: Advancements in Macromolecular Therapeutics for Neurodegenerative Diseases and Strategies to Overcome the Blood–Brain Barrier
Alo, B., & Lamers, C. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00153 · Cited by 10
First dual binder of microRNA-146a and monomeric tau: a novel approach for multitargeted therapeutics for neurodegenerative diseases
Gabr, M. T., & Barbault, F. (2020) · Chemical Communications · doi:10.1039/d0cc04249h · Cited by 10
Modern care for patients with Alzheimer disease: rationale for early intervention.
Galluzzi, K. E., Appelt, D. M., & Balin, B. J. (2010) · PubMed · Cited by 10
Role of computational and structural biology in the development of small-molecule modulators of the spliceosome
Rozza, R., Janoš, P., Spinello, A., & Magistrato, A. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2114452 · Cited by 10
Personalized Medicine and Resurrected Hopes for the Management of Alzheimer’s Disease: A Modular Approach Based on GSK-3β Inhibitors
Arafa, R. K., & Elghazawy, N. H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-60733-7_11 · Cited by 10
Heparan sulfate proteoglycans: Mediators of cellular and molecular Alzheimer's disease pathogenic factors via tunnelling nanotubes?
Nguyen, D. L., Okolicsanyi, R. K., & Haupt, L. M. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103936 · Cited by 9
Evaluating computational and experimental approaches in early-stage Alzheimer’s drug discovery: a systematic review
Azmal, M., Paul, J. K., Shohan, M. N. H., Haque, A. N. M. S. N. B., Mrinmoy, M., Talukder, O. F., & Ghosh, A. (2025) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-025-00610-7 · Cited by 9
Characterization and application studies of ProxyPhos, a chemosensor for the detection of proximally phosphorylated peptides and proteins in aqueous solutions
Kraskouskaya, D., Cabral, A. D., Fong, R. B., Bancerz, M., Toutah, K., Rosa, D. A., Gardiner, J. E., de Araujo, E. D., Duodu, E., Armstrong, D. R., et al. (2017) · The Analyst · doi:10.1039/c6an02537d · Cited by 9
Modeling of age‐dependent amyloid accumulation and γ‐secretase inhibition of soluble and insoluble Aβ in a transgenic mouse model of amyloid deposition
PARKINSON, J. R., Ploeger, B. A., Appelkvist, P., Bogstedt, A., Bergstedt, K. D., Eketjäll, S., & Visser, S. A. G. (2013) · Pharmacology Research & Perspectives · doi:10.1002/prp2.12 · Cited by 9
Subgroup differences in ‘brain-type’ transferrin and α-synuclein in Parkinson’s disease and multiple system atrophy
Yoshihara, A., Fukatsu, M., Hoshi, K., Ito, H., Nollet, K. E., Yamaguchi, Y., Ishii, R., Tokuda, T., Miyajima, M., Arai, H., et al. (2016) · The Journal of Biochemistry · doi:10.1093/jb/mvw015 · Cited by 9
Angiotensin-converting enzyme gene insertion-deletion polymorphism is a risk marker for Alzheimer’s disease in a Chinese population: a meta-analysis of case–control studies
Yuan, Y., Piao, J., Ma, K., & Lu, N. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-015-1368-6 · Cited by 9
Mechanism of NLRP3 inflammasome activation and its role in Alzheimer’s disease
Gao, X., Zhang, X., Sun, Y., & Dai, X. (2022) · Exploration of Immunology · doi:10.37349/ei.2022.00048 · Cited by 8
Alzheimer diseases
Savonenko, A. V., Wong, P. C., & Li, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00022-8 · Cited by 8
What to Look for Beyond “Pathogenic” Factors in Senile Dementia? A Functional Deficiency of Ca 2+ Signaling
Chen, M., Nguyen, H. T., & Sawmiller, D. R. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111142 · Cited by 8
Designed Cell-Penetrating Peptide Constructs for Inhibition of Pathogenic Protein Self-Assembly
Kalmouni, M., Oh, Y., Alata, W., & Magzoub, M. M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111443 · Cited by 7
Strategizing the Development of Alzheimer’s Therapeutics
Davis, J. B., & Couch, R. D. (2014) · Advances in Alzheimer s Disease · doi:10.4236/aad.2014.33011 · Cited by 7
A Practical Guide for Exploring Opportunities of Repurposing Drugs for CNS Diseases in Systems Biology
Mei, H., Feng, G., Zhu, J., Lin, S. M., Qiu, Y., Wang, Y., & Xia, T. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2627-5_33 · Cited by 7
Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice
Gozes, I. (2010) · The EPMA Journal · doi:10.1007/s13167-010-0029-y · Cited by 7
Network pharmacology used to decode potential active ingredients in Ferula assafoetida and mechanisms for the application to Alzheimer’s disease
Xu, M. Q., Zhang, L., Li, P., Wang, C., & Shi, Y. (2020) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2020.04.002 · Cited by 7
Yeast‐derived vacuoles as a novel carrier with enhanced hCMEC/D3 cell monolayer penetration
Nguyen, N.-H. T., Nguyen, N., Kim, Y., & Min, J. (2022) · Biotechnology Journal · doi:10.1002/biot.202200393 · Cited by 7
The Role of Glycogen Synthase Kinase-3 (GSK-3) in Alzheimer’s Disease
Medina, M., & Avil, J. (2011) · InTech eBooks · doi:10.5772/16879 · Cited by 7
Drug Development for Alzheimer's Disease: Recent Progress
Ji, W., & Ha, I. (2010) · Experimental Neurobiology · doi:10.5607/en.2010.19.3.120 · Cited by 7
Alzheimer's disease: A need for personalized therapeutic approaches
Frenkel, D. (2020) · Drug Development Research · doi:10.1002/ddr.21652 · Cited by 7
Hyperphosphorylated tau-based Alzheimer’s Disease drug discovery: Identification of inhibitors of tau aggregation and cytotoxicity
Hagar, H. C., Fernández-Vega, V., Wang, K., Jordan, L. M. O., Shumate, J., Scampavia, L. D., Tapayan, A. S., Nguyen, H. M., Spicer, T., & Kuo, M. (2025) · SLAS DISCOVERY · doi:10.1016/j.slasd.2025.100235 · Cited by 6
AlphaScreen Identifies MSUT2 Inhibitors for Tauopathy-Targeting Therapeutic Discovery
Baker, J. D., Uhrich, R. L., Strovas, T. J., Saxton, A. D., & Kraemer, B. C. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220958387 · Cited by 6
Historical perspectives on the discovery and development of drugs to treat neurological disorders
Williams, M. J., & COYLE, J. T. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.008 · Cited by 6
Neuroprotective Strategies for Alzheimer’s Disease Prevention and Therapy
Simmons, D. A., Yang, T., Massa, S. M., & Longo, F. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00016-2 · Cited by 6
Nanomarker for Early Detection of Alzheimer’s Disease Combining Ab initio DFT Simulations and Molecular Docking Approach
Schopf, P. F., Zanella, I., Cordeiro, M. N. D. S., Ruso, J. M., González‐Durruthy, M., & Martins, M. O. (2021) · Biophysica · doi:10.3390/biophysica1020007 · Cited by 6
Drosophila melanogaster as a Model for Studies on the Early Stages of Alzheimer’s Disease
Lim, J. Y., Ott, S., & Crowther, D. C. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2627-5_13 · Cited by 6
Tau Protein Associated Inhibitors in Alzheimer Disease
Li, Q., Chu, T., Chen, Y., & Li, Y. (2014) · Chinese Journal of Chemistry · doi:10.1002/cjoc.201400469 · Cited by 6
Identification of small molecules and related targets that modulate tau pathology in a seeded primary neuron model
Gibbons, G. S., Gould, H., Lee, V. M. ‐., Crowe, A., & Brunden, K. R. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104876 · Cited by 5
Self-citation
The microtubule-dynamin binding inhibitor peptide PHDP5 rescues spatial learning and memory deficits in Alzheimer’s disease model mice
Chang, C.-J., Taoufiq, Z., Yamada, H., Takei, K., Tomiyama, T., Umeda, T., Hori, T., & Takahashi, T. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148987 · Cited by 5
A novel phosphodiesterase 5 inhibitor, RF26, improves memory impairment and ameliorates tau aggregation and neuroinflammation in the P301S tauopathy mouse model of Alzheimer's disease
El-Desouky, S., Abdel‐Halim, M., Fathalla, R. K., Abadi, A., Piazza, G. A., Salama, M., El‐Khodery, S., Youssef, M. A., & Elfarrash, S. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.115058 · Cited by 5
Towards Small Molecules as Therapies for Alzheimer’s Disease and Other Neurodegenerative Disorders
Aziz, O., Bürli, R. W., Fischer, D. F., Frearson, J. A., & Wall, M. D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50004-0 · Cited by 5
The contribution of N-terminally modified amyloid beta to the etiology of Alzheimer's disease
Wittnam, J. L. (2012) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-3182 · Cited by 5
Frontotemporal Lobar Degeneration: New Understanding Brings New Approaches
Tartaglia, M. C. (2012) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2011.11.009 · Cited by 4
Soy lysolecithin prevents hypertension and cognitive impairment induced in mice by high salt intake by inhibiting intestinal inflammation
Kubota, H., Kunisawa, K., Hasegawa, M., Kurahashi, H., Kagotani, K., Fujimoto, Y., Hayashi, A., Ryoji, S. O. N. O., Tsuji, T., Saito, K., et al. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105858 · Cited by 4
Polyprenols mitigate cognitive dysfunction and neuropathology in the APP/PS1 mouse
Zhuang, X., Zang, X., Zheng, G., Hua, N., Sun, Y., Hu, Y., & He, L. (2018) · Phytotherapy Research · doi:10.1002/ptr.6050 · Cited by 4
Investigation of memory-enhancing botanical mixture and their isolated compounds for inhibition of amyloid-β and tau aggregation
Baek, S., Park, S., Shin, J., Lee, J., Kim, H. Y., Han, G., & Kim, Y. S. (2020) · Applied Biological Chemistry · doi:10.1186/s13765-020-00507-z · Cited by 4
Synchrotron Small Angle X-Ray Scattering Quantitatively Detects Angstrom Level Changes in the Average Radius of Taxol-Stabilized Microtubules Decorated with the Microtubule-Associated-Protein Tau
Choi, M. C., Raviv, U., Li, Y., Miller, H. P., Needleman, D. J., Kim, M. W., Wilson, L., Feinstein, S. C., & Safinya, C. R. (2011) · Journal of Physics Conference Series · doi:10.1088/1742-6596/272/1/012001 · Cited by 4
Pin1 Regulatory miRNAs as Novel Candidates for Alzheimer’s Disease TreatmentPreprint
Heidari, E., Siavashani, E. S., Rasooli, M., Amiri, Z., Sharifi‐Zarchi, A., & Shahpasand, K. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/472985 · Cited by 4
Therapeutic potential of small peptides in Alzheimer's disease: Advances in memory restoration and targeted delivery systems
Verma, P., Khatun, R., Jew, K. A., Prusty, S. K., & Knafo, S. (2025) · Neuropeptides · doi:10.1016/j.npep.2025.102559 · Cited by 3
Candidate Bio-Markers of Alzheimer’s Disease
Binukumar, B. K., & Harish, C. (2013) · InTech eBooks · doi:10.5772/55069 · Cited by 3
Network Pharmacology for Drug Repositioning in Anti-Alzheimer’s Drug Development
Dash, R., Munni, Y. A., Mitra, S., Dash, N., & Moon, I. S. (2023) · Neuromethods · doi:10.1007/978-1-0716-3311-3_15 · Cited by 4
Design of an Orally Bioavailable Small Molecule That Modulates the Microtubule-Associated Protein Tau’s Pre-mRNA Splicing
Zhang, P., Taghavi, A., Abe, M., Aikawa, H., Akahori, Y., Chen, J. L., Tong, Y., Baisden, J. T., Cameron, M. D., Childs‐Disney, J. L., et al. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00260 · Cited by 3
Stem Cell Approaches for Treatment of Neurodegenerative Diseases
Anand, S. (2014) · Clinical Pharmacology & Biopharmaceutics · doi:10.4172/2167-065x.1000126 · Cited by 3
The Progress of the Anticancer Agents Related to the Microtubules Target
Olatunde, O. Z., Yong, J., & Lu, C. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666200729162510 · Cited by 3
GPCR, a rider of Alzheimer’s disease
Liu, X., & Zhao, J. (2011) · Frontiers in Biology · doi:10.1007/s11515-011-1129-3 · Cited by 3
Polymeric Nanomedicine
Zhao, Y., Zheng, C., & Liu, Y. (2019) · Springer eBooks · doi:10.1007/978-981-13-8731-9_9 · Cited by 3
Imaging Biomarkers for Diagnosis, Prognosis and Treatment of Alzheimer's Disease
Skovronsky, D., & Feuerstein, G. (2012) · Frontiers in neuroscience · doi:10.1201/b11986-4 · Cited by 2
Recent advances in GABAA receptor targeting ligands
Zuo, Y., Zhao, Y., Liu, G., & Sun, Q. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118651 · Cited by 2
RECENT ADVANCES IN THE MANAGEMENT OF ALZHEIMER’S DISEASE
Chandrashekar, K. S., Meti, V., & Saritha, M. (2013) · Cited by 2
Emerging pharmacology of targeted protein degraders
Barghout, S. H., & Eldeeb, M. A. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103694 · Cited by 2
Prévenir la progression de la pathologie Tau par immunothérapie passive
Ozmen, L., & Collin, L. (2015) · médecine/sciences · doi:10.1051/medsci/20153102006 · Cited by 2
Preclinical models of Alzheimer’s disease for identification and preclinical validation of therapeutic targets: from fine-tuning strategies for validated targets to new venues for therapy
Vasconcelos, B., Bird, M., Stancu, I., Terwel, D., & Dewachter, I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805120-7.00006-3 · Cited by 2
Profiling Brain Trauma in Professional American-style Football and the Implications to Developing Neurological Injury
Karton, C. (2019) · uO Research (University of Ottawa) · doi:10.20381/ruor-24220 · Cited by 2
In silico designed microtubule-stabilizer drugs against tauopathy in Alzheimer’s disease
Sarukhanyan, E., & Dandekar, T. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2139760 · Cited by 1
Exosomal RNA in aging-related diseases
Das, S., & Paul, A. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14008-2.00002-4 · Cited by 1
CYR61 Acts as an Intracellular Microtubule-Associated Protein and Coordinates Mitotic Progression via PLK1-FBW7 Pathway
Hu, K., Xie, L., Wu, W., Zhang, J., Li, Y., He, J., Zhang, Y., Lu, D., Koeffler, H. P., Lin, L., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.93335 · Cited by 1
Nanotheranostic Approach for Targeting Tauopathies in Alzheimer's Disease: Mechanistic Insight and Recent Advances
Sahu, K. K., Chaudhary, R., Farooqi, M. A., & Kaurav, M. (2024) · Drug Delivery Letters · doi:10.2174/0122103031331346241122152643 · Cited by 1
Anti-cis P-tau attenuates tauopathy and enhances cognitive function following global cerebral ischemia in mice
Sadeghzadeh, J., Roqanian, S., Jafarzadeh, J., Zangbar, H. S., Nakhjiri, E., Kalan, A. E., Farhoudi, M., Ahmadian, S., Shahabi, P., & Shahpasand, K. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114834 · Cited by 1
Peptide-based therapeutics in the management of Alzheimer’s disease (AD) and their potential to develop novel strategies
Nabi, S. U., Rasool, I., Khan, A., Haq, A. U., Hussain, I., Khan, M. S., Majid, S., Rashid, S., Rashid, S. M., Sehar, N., et al. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-025-01781-w · Cited by 1
PIAS1-mediated GSK3β SUMOylation exacerbates tauopathy and cognitive deficits in Alzheimer’s disease models
Qiu, Y., Wu, S., Zhong, Y., Fan, D., Tong, Q., Xiong, J., Xu, K., Liu, G., Liu, E. J., Li, X. W., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03740-y · Cited by 1
An Overview of Target Specific Neuro-Protective and Neuro-Restorative Strategies
Al, A., Al, K., Al-, A., Arshaduddin, M., & Tariq, M. (2012) · InTech eBooks · doi:10.5772/34731 · Cited by 1
Epotilony – nadzieja dla pacjentów niewrażliwych na leczenie taksanami
Rogalska, A., Marczak, A., Szwed, M., Gajek, A., & Jóźwiak, Z. (2010) · Współczesna Onkologia · doi:10.5114/wo.2010.14131 · Cited by 1
Neuroprotective Activity ofSibjeondaebo-tangon A β Peptide-Induced Damages
Yim, H.-J., Lim, J. H., Kim, M. H., Namgung, U., Lee, S. R., & Jung, I. C. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/459894 · Cited by 1
Role of the Mitochondrial Fission Protein Drp1 in Synaptic Damage and Neurodegeneration
Nakamura, T., Cho, D., & Lipton, S. A. (2011) · Springer eBooks · doi:10.1007/978-94-007-1291-1_8 · Cited by 1
Tau in Tauopathies That Leads to Cognitive Disorders and in Cancer
Huda, M. N., & Pan, C. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.74025 · Cited by 1
CNS Drugs
Lowe, J. A., III (2013) · Drug Discovery · doi:10.1002/9781118354483.ch7 · Cited by 1
Current Perspectives of Nanotherapeutics for the Treatment of Alzheimer’s Disease
Mishra, S., Senthilkumar, D., & Yadav, V. K. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815256505124010010 · Cited by 1
Developing an Alzheimer’s Disease Therapeutic: Identification and Validation of Signaling Pathways Involved in Small Molecule Induction of Nerve Growth Factor
Davis, J. B. (2016) · doi:10.13021/mars/7006 · Cited by 1
Elucidating a Role for Glycogen Synthase Kinase-3 in the Regulation of Neuronal Oscillatory Function: Relevance to Learning and Memory
Albeely, A. M. (2022) · The Atrium (University of Guelph) · doi:10.1007/s10571-020-01020-z · Cited by 1
Implication du récepteur LSR (lipolysis stimulated lipoprotein receptor) dans le contrôle de l’homéostasie du cholestérol cérébral et les capacités cognitives au cours du vieillissement
Pinçon, A. (2014) · theses.fr (ABES) · doi:10.70675/6098b314z1123z4208za0e0z06d382f77a3e · Cited by 1
The novel role of the neuropeptides orexin and QRFP and their involvement in Alzheimer's disease
Davies, J. (2014) · Brunel University Research Archive (BURA) (Brunel University London)
Neuroligins and Neurexins in Alzheimer’s disease
Sindi, I. A. (2014) · The University of Queensland · doi:10.14264/uql.2015.176
Tolfenamic Acid: A Potential Modifier of Tau Protein in Alzheimer's Disease
Chang, J. C. (2015) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/thesis-chang-joanna-2015
Structural and Toxic Properties of Protein Aggregates: Towards a Molecular Understanding of Alzheimer's Disease
Wang, L., & Campioni, S. (2011) · InTech eBooks · doi:10.5772/20922

Authors: Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y.
Affiliations: University of Pennsylvania (US)
Corresponding author: Brunden, Kurt R.
ORCID: Brunden, Kurt R.
Trojanowski, John Q.
Lee, Virginia M.-Y.
Venue: Nature Reviews Drug Discovery
Publisher: Springer Science and Business Media LLC
Published: 2009-10
Volume: 8
Issue: 10
Pages: 783-793
ISSN: 1474-1776 (ISSN-L)
1474-1784
DOI: 10.1038/nrd2959
PMC: PMC2787232
OpenAlex: W2021370614
Cited by: 440
References: 140
Citations by year: 2026: 7 · 2025: 12 · 2024: 20 · 2023: 12 · 2022: 17 · 2021: 31 · 2020: 28 · 2019: 23 · 2018: 22 · 2017: 30 · 2016: 30 · 2015: 22 · 2014: 40 · 2013: 31 · 2012: 43
FWCI: 4.24
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5u01ag024904-10)
National Institute on Aging (U01-AG-024904, P01AG014382, P01 AG11542, P01-AG09215, P30AG10124, P01AG011542, P01 AG-17586, P01AG014449, P01 AG14382, P30AG010124, P01AG009215, P01AG017586, P01 AG14449, UO1 AG24904, U19AG010483, P01-AG19724, P01AG019724)
National Institute of Neurological Disorders and Stroke (P01NS044233)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: tau protein, tauopathy, Alzheimer's disease, tau misfolding, neurodegeneration, tau functions, microtubule-associated proteins
MeSH terms: Alzheimer Disease, Animals, Humans, tau Proteins, Tauopathies, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks